

Jean J Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4579369/publications.pdf>

Version: 2024-02-01

103
papers

12,906
citations

50566

48
h-index

39744

98
g-index

110
all docs

110
docs citations

110
times ranked

23023
citing authors

#	ARTICLE	IF	CITATIONS
1	Blocking PI3K p110 ^β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 673-685.	1.5	6
2	Sarm1 activation produces cADPR to increase intra-axonal Ca ⁺⁺ and promote axon degeneration in PIPN. <i>Journal of Cell Biology</i> , 2022, 221, .	2.3	44
3	Temporal and spatial topography of cell proliferation in cancer. <i>Nature Cell Biology</i> , 2022, 24, 316-326.	4.6	34
4	p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. <i>Nature Communications</i> , 2022, 13, 1473.	5.8	10
5	Targeting CDK4 and CDK6 in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 356-372.	12.8	125
6	Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake. <i>Cell Reports</i> , 2022, 38, 110509.	2.9	5
7	Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids. <i>Nano Letters</i> , 2022, 22, 4058-4066.	4.5	8
8	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	68
9	Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
10	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021, 2, 34-48.	5.7	48
11	The role of the PIK3CA gene in the development and aging of the brain. <i>Scientific Reports</i> , 2021, 11, 291.	1.6	3
12	Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling. <i>Science Advances</i> , 2021, 7, .	4.7	2
13	Disrupted PI3K subunit p110 ^β signaling protects against pulmonary hypertension and reverses established disease in rodents. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	12
14	How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic Resistance in Cancer. <i>Cancer Research</i> , 2021, 81, 6074-6077.	0.4	16
15	Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. <i>Oncogene</i> , 2020, 39, 50-63.	2.6	43
16	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii9-ii9.	0.4	0
17	Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. <i>Cell Reports</i> , 2020, 32, 108196.	2.9	13
18	PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K- β inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24427-24433.	3.3	12

#	ARTICLE	IF	CITATIONS
19	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1352-1373.	7.7	145
20	Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. <i>Science Advances</i> , 2020, 6, eabb2210.	4.7	46
21	High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. <i>Science Signaling</i> , 2020, 13, .	1.6	44
22	Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. <i>Clinical Cancer Research</i> , 2020, 26, 5557-5566.	3.2	25
23	A sequential methodology for the rapid identification and characterization of breast cancer-associated functional SNPs. <i>Nature Communications</i> , 2020, 11, 3340.	5.8	17
24	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology</i> , 2020, 22, ii228-ii228.	0.6	0
25	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 741-750.	0.8	103
26	Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method. <i>Scientific Reports</i> , 2019, 9, 622.	1.6	20
27	Targeted Profiling of RNA Translation. <i>Current Protocols in Molecular Biology</i> , 2019, 125, e71.	2.9	4
28	PI3K alpha and delta promote hematopoietic stem cell activation. <i>JCI Insight</i> , 2019, 4, .	2.3	31
29	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. <i>Cancer Cell</i> , 2018, 33, 173-186.e5.	7.7	201
30	Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells. <i>Cancer Research</i> , 2018, 78, 2248-2261.	0.4	66
31	Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. <i>Clinical Cancer Research</i> , 2018, 24, 1795-1804.	3.2	67
32	Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1339-1342.	0.8	11
33	PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. <i>Cell Reports</i> , 2018, 25, 2972-2980.e5.	2.9	381
34	BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1 α activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9600-E9609.	3.3	20
35	A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. <i>IScience</i> , 2018, 9, 149-160.	1.9	12
36	Structure-Based Drug Design and Identification of H ₂ O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8613-8624.	2.9	27

#	ARTICLE	IF	CITATIONS
37	Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9325-E9332.	3.3	28
38	Dual HDAC and PI3K Inhibition Abrogates NF κ B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Research, 2018, 78, 4007-4021.	0.4	60
39	CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends in Cell Biology, 2018, 28, 911-925.	3.6	273
40	Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget, 2018, 9, 23878-23889.	0.8	11
41	Pik3ca is required for mouse uterine gland development and pregnancy. PLoS ONE, 2018, 13, e0191433.	1.1	8
42	An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. ELife, 2018, 7, .	2.8	91
43	PI3Kinase Alpha and Delta Promote Hematopoietic Stem Activation Under Stress. Blood, 2018, 132, 329-329.	0.6	0
44	Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell, 2017, 31, 576-590.e8.	7.7	84
45	PI3K-p110 β mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85 β . Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7095-7100.	3.3	75
46	The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 123-131.	3.3	117
47	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature, 2017, 549, 533-537.	13.7	350
48	CRKL Mediates p110 β -Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Reports, 2017, 20, 549-557.	2.9	33
49	CDK4/6 inhibition triggers anti-tumour immunity. Nature, 2017, 548, 471-475.	13.7	998
50	Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro-Oncology, 2017, 19, 22-30.	0.6	32
51	MELK is not necessary for the proliferation of basal-like breast cancer cells. ELife, 2017, 6, .	2.8	86
52	PI3K β inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction. JCI Insight, 2017, 2, .	2.3	21
53	Discovery of a Series of 5,11-Dihydro-6 <i>H</i> -benzo[<i>e</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-6-ones as Selective PI3K β Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 908-912.	1.3	15
54	Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9810-9815.	3.3	66

#	ARTICLE	IF	CITATIONS
55	Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. <i>Gynecologic Oncology</i> , 2016, 142, 548-556.	0.6	80
56	PI3K in the ventromedial hypothalamic nucleus mediates estrogenic actions on energy expenditure in female mice. <i>Scientific Reports</i> , 2016, 6, 23459.	1.6	32
57	NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K/AKT and JAK/STAT3 pathways. <i>Cell Discovery</i> , 2016, 2, 16030.	3.1	17
58	Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13156-13161.	3.3	12
59	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.	15.2	105
60	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. <i>Cell Reports</i> , 2016, 15, 2692-2704.	2.9	92
61	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016, 29, 255-269.	7.7	356
62	Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. <i>Oncotarget</i> , 2016, 7, 13153-13166.	0.8	66
63	CDK4/6 inhibition: the late harvest cycle begins. <i>Oncotarget</i> , 2016, 7, 48854-48856.	0.8	4
64	Rac1-mediated membrane raft localization of PI3K/p110 ^β is required for its activation by GPCRs or PTEN loss. <i>ELife</i> , 2016, 5, .	2.8	25
65	Measurement of PIP3 Levels Reveals an Unexpected Role for p110 ^β in Early Adaptive Responses to p110 ^β -Specific Inhibitors in Luminal Breast Cancer. <i>Cancer Cell</i> , 2015, 27, 97-108.	7.7	165
66	Bioprinting for cancer research. <i>Trends in Biotechnology</i> , 2015, 33, 504-513.	4.9	313
67	Chemopreventive effects of aspirin at a glance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 254-263.	3.3	26
68	Light-Triggered, Self-Immolative Nucleic Acid-Drug Nanostructures. <i>Journal of the American Chemical Society</i> , 2015, 137, 6112-6115.	6.6	179
69	Role of Phosphoinositide 3-OH Kinase p110 ^β in Skeletal Myogenesis. <i>Molecular and Cellular Biology</i> , 2015, 35, 1182-1196.	1.1	21
70	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. <i>Cell</i> , 2015, 163, 174-186.	13.5	346
71	A PI3K p110 ^β -Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. <i>Nature Communications</i> , 2015, 6, 8501.	5.8	44
72	The ER ^α -PI3K Cascade in Proopiomelanocortin Progenitor Neurons Regulates Feeding and Glucose Balance in Female Mice. <i>Endocrinology</i> , 2015, 156, 4474-4491.	1.4	33

#	ARTICLE	IF	CITATIONS
73	PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. <i>Nature Reviews Cancer</i> , 2015, 15, 7-24.	12.8	1,083
74	Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. <i>ELife</i> , 2015, 4, .	2.8	79
75	MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. <i>ELife</i> , 2014, 3, e01763.	2.8	104
76	Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110 α . <i>Journal of Clinical Investigation</i> , 2014, 124, 1794-1809.	3.9	48
77	PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6395-6400.	3.3	66
78	Cyclin C is a haploinsufficient tumour suppressor. <i>Nature Cell Biology</i> , 2014, 16, 1080-1091.	4.6	124
79	The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome. <i>Cell Cycle</i> , 2013, 12, 3589-3593.	1.3	3
80	Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention. <i>Cancer Discovery</i> , 2013, 3, 44-51.	7.7	47
81	Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. <i>Genes and Development</i> , 2013, 27, 1568-1580.	2.7	19
82	Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies. , 2013, , .		0
83	Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110 β as a Potential Anticancer Agent. <i>Cancer Discovery</i> , 2012, 2, 425-433.	7.7	152
84	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. <i>Journal of Biological Chemistry</i> , 2012, 287, 9742-9752.	1.6	89
85	The p110 α and p110 β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. <i>Genes and Development</i> , 2012, 26, 1573-1586.	2.7	116
86	The p110 α and p110 δ Isoforms of PI3 Kinase Are Dispensable for Hematopoietic Stem Cell Self-Renewal but Have Redundant Roles in B Cell Differentiation.. <i>Blood</i> , 2012, 120, 2322-2322.	0.6	0
87	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway α -dependent and PI3K pathway β -independent mechanisms. <i>Nature Medicine</i> , 2011, 17, 1116-1120.	15.2	231
88	The Acute Effects of Leptin Require PI3K Signaling in the Hypothalamic Ventral Premammillary Nucleus. <i>Journal of Neuroscience</i> , 2011, 31, 13147-13156.	1.7	66
89	Specific Roles of the p110 α Isoform of Phosphatidylinositol 3-Kinase in Hepatic Insulin Signaling and Metabolic Regulation. <i>Cell Metabolism</i> , 2010, 11, 220-230.	7.2	119
90	PI3K Signaling in the Ventromedial Hypothalamic Nucleus Is Required for Normal Energy Homeostasis. <i>Cell Metabolism</i> , 2010, 12, 88-95.	7.2	96

#	ARTICLE	IF	CITATIONS
91	Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis. <i>Endocrinology</i> , 2009, 150, 4874-4882.	1.4	82
92	Estrogen Receptor- α Negative Breast Cancer: New Insights into Subclassification and Targeting. <i>Clinical Cancer Research</i> , 2009, 15, 6309-6310.	3.2	2
93	Should individual PI3 kinase isoforms be targeted in cancer?. <i>Current Opinion in Cell Biology</i> , 2009, 21, 199-208.	2.6	106
94	Targeting the phosphoinositide 3-kinase pathway in cancer. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 627-644.	21.5	2,218
95	The p110 β Catalytic Isoform of PI3 Kinase Is Important for Erythropoiesis, but Has a Minimal Role in Hematopoietic Stem Cell Self-Renewal.. <i>Blood</i> , 2009, 114, 3620-3620.	0.6	0
96	Essential roles of PI(3)K- β in cell growth, metabolism and tumorigenesis. <i>Nature</i> , 2008, 454, 776-779.	13.7	654
97	The p110 β Isoform of Phosphatidylinositol 3-Kinase Is Essential for Polyomavirus Middle T Antigen-Mediated Transformation. <i>Journal of Virology</i> , 2007, 81, 7069-7076.	1.5	28
98	Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene. <i>Cell</i> , 2007, 129, 1065-1079.	13.5	538
99	PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target. <i>Science's STKE: Signal Transduction Knowledge Environment</i> , 2006, 2006, pe52-pe52.	4.1	36
100	The p110 β isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16296-16300.	3.3	201
101	The oncogenic properties of mutant p110 β and p110 δ phosphatidylinositol 3-kinases in human mammary epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18443-18448.	3.3	313
102	Functional genetics and experimental models of human cancer. <i>Trends in Molecular Medicine</i> , 2004, 10, 344-350.	3.5	56
103	Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. <i>Cancer Cell</i> , 2003, 3, 483-495.	7.7	262